Why the study?
The study was conducted to evaluate the effect of cardiac contractility modulation in patients with chronic heart failure and atrial fibrillation.
Does implantation of a cardiac contractility modulator improve LV remodeling, functional class, and NT-proBNP levels in patients with chronic heart failure and atrial fibrillation?
Does implantation of a cardiac contractility modulator improve LV remodeling, functional class, and NT-proBNP levels in patients with chronic heart failure and atrial fibrillation?
Cardiac contractility modulation may be a promising adjunctive treatment for improving LV remodeling and functional status in patients with concurrent chronic heart failure and atrial fibrillation.
Aim : to study the effect of cardiac contractility modulation (CCM) in patients with chronic heart failure (CHF) and atrial fibrillation (AF). Materials and methods . In a group of 100 patients with CHF and AF, the following studies were performed before implantation of the CCM and after 6 months of follow-up: 12-channel ECG, transthoracic Echocardiography, 6-minute walk test, determination of the level of pro-natriuretic N-terminal peptide (NT-proBNP), and a questionnaire based on the Minnesota quality of life questionnaire for patients with CHF (MHFLQ). All patients received long-term optimal medication therapy for CHF before surgery. Results . The results show a positive effect of the use of MCC in patients with CHF and AF on reverse LV remodeling, functional class of CHF, and levels of NT-pro-BNP regardless of the form of AF. Conclusion . The use of MCC may be a promising treatment method in addition to optimal medication therapy in patients with CHF and AF.
No takes yet. Share an insight, caveat, or question.
Uskach et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: